These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 758043)

  • 81. Prolactin changes in maternal plasma following termination by vacuum curettage and the effect of bromocriptine treatment on these changes.
    Ylikorkala O; Rönnberg L
    Br J Obstet Gynaecol; 1980 Oct; 87(10):911-5. PubMed ID: 7426491
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The effect of prolactin on androgen response to human chorionic gonadotropin in normal men.
    Lackritz RM; Bartke A
    Fertil Steril; 1980 Aug; 34(2):140-3. PubMed ID: 6773818
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Evidence that androgens are involved in atresia and anovulation induced by antiprogesterone RU486 in rats.
    Sánchez-Criado JE; Tébar M; Sánchez A; Gaytán F
    J Reprod Fertil; 1993 Sep; 99(1):173-9. PubMed ID: 8283435
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH, and prolactin.
    Cushman P; Kreek MJ
    N Y State J Med; 1974 Oct; 74(11):1970-3. PubMed ID: 4528642
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
    Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
    Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effects of bromocriptine and naloxone on plasma levels of prolactin, LH and FSH during suckling in the female rat: responses to gonadotrophin releasing hormone.
    Sirinathsinghji DJ; Martini L
    J Endocrinol; 1984 Feb; 100(2):175-82. PubMed ID: 6420492
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Hormone blood levels in patients with prostatic carcinoma and their relation to the type of carcinoma growth differentiation.
    Bartsch W; Steins P; Becker H
    Eur Urol; 1977; 3(1):47-52. PubMed ID: 837954
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Bromocriptine for male infertility.
    Saidi K; Wenn RV; Sharif F
    Lancet; 1977 Jan; 1(8005):250-1. PubMed ID: 64770
    [No Abstract]   [Full Text] [Related]  

  • 89. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome.
    Buvat J; Buvat-Herbaut M; Marcolin G; Racadot A; Fourlinnie JC; Fossati P
    Fertil Steril; 1985 Sep; 44(3):356-60. PubMed ID: 3161758
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
    Katayama T; Umeda K; Kazama T
    Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Prostatic cancer.
    Blacklock NJ
    Urol Res; 1977; 5(1):1-5. PubMed ID: 324081
    [No Abstract]   [Full Text] [Related]  

  • 92. Androgen substitution with testosterone containing nasal drops.
    Danner C; Frick J
    Int J Androl; 1980 Aug; 3(4):429-35. PubMed ID: 6777309
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation.
    Wilson DW; Harper ME; Jensen HM; Ikeda RM; Richards G; Peeling WB; Pierrepoint CG; Griffiths K
    Prostate; 1985; 7(2):131-41. PubMed ID: 3931066
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A new PTP parameter as potential predictor of prostate cancer response to therapy.
    Tarle M
    Int J Rad Appl Instrum B; 1988; 15(2):225-7. PubMed ID: 3366623
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Neuroendocrine effects of chronic neuroleptic therapy in male psychiatric patients.
    Martin-du Pan R; Baumann P; Magrini G; Felber JP
    Psychoneuroendocrinology; 1978 Oct; 3(3-4):245-52. PubMed ID: 34841
    [No Abstract]   [Full Text] [Related]  

  • 96. A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Why and How?
    Costello LC; Franklin RB
    J Clin Res Oncol; 2019; 2(1):. PubMed ID: 30828702
    [TBL] [Abstract][Full Text] [Related]  

  • 97. In Reply to Hurmuz and Ozyigit.
    Bryant AK; Rose BS
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):225. PubMed ID: 30967234
    [No Abstract]   [Full Text] [Related]  

  • 98. In Regard to Bryant et al.
    Hurmuz P; Ozyigit G
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):224-225. PubMed ID: 30967233
    [No Abstract]   [Full Text] [Related]  

  • 99. Changes in Use of Oral Androgen Pathway Directed Medications during the COVID-19 Era.
    Rosen GH; Davies BJ; Murray KS
    Urol Pract; 2022 Jul; 9(4):279-283. PubMed ID: 37145775
    [No Abstract]   [Full Text] [Related]  

  • 100. Understanding the role of dopamine in cancer: past, present and future.
    Grant CE; Flis AL; Ryan BM
    Carcinogenesis; 2022 Jun; 43(6):517-527. PubMed ID: 35616105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.